FDA Official Says Personalized Medicine Regulation Taking Shape Following Zelboraf, Xalkori Success
February 01, 2012
FDA Official Says Personalized Medicine Regulation Taking Shape Following Zelboraf, Xalkori Success
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Qiagen's Experience Developing KRAS CDx for Erbitux Yields Lessons for Rx/Dx Development
November 28, 2012 / Pharmacogenomics Reporter - Pfizer, Roche Officials Share Lessons Learned from Rx/Dx Co-development of Xalkori and Zelboraf
February 29, 2012 / Pharmacogenomics Reporter - Personalized Medicine in 2011: Some Successes, Slow Progress, Continued Economic Woes
January 4, 2012 / Pharmacogenomics Reporter - FDA's Reorganization of Oncology Office May Be Good for PGx-Guided Drugs
September 14, 2011 / Pharmacogenomics Reporter - Pfizer, Abbott Ink Deal to Develop Companion Dx for PGx-based NSCLC Drug
September 2, 2009 / Pharmacogenomics Reporter